Skip to content

Clinical and Basic Research on External Treatment of Traditional Chinese Medicine Synthetically Preventing and Treating Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy

Clinical and Basic Research on External Treatment of Traditional Chinese Medicine Synthetically Preventing and Treating Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070161
Enrollment
Unknown
Registered
2023-04-04
Start date
2023-04-08
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

External treatment group:fire dragon moxibustion combined with acupoint catgut embedding, colony stimulating factor
Control group:colony stimulating factor

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Meeting the diagnostic code that was diagnosed with invasive breast cancer in the histologic examination (2) Chemotherapy was administered on a standard three-week regimen (3) Female, aged 18-70 (4) Karnofsky score was =75, and the predicted survival time was more than 3 months (5) Without serious cardiovascular and cerebrovascular diseases, digestive diseases, or mental diseases; blood routine examination, liver and kidney function, heart function, and electrocardiogram were normal before chemotherapy (6) Has not received any treatment for breast cancer in the past 1 month (7) Asked for informed consent and voluntary participation

Exclusion criteria

Exclusion criteria: Exclusion Criteria (1)Does not meet the inclusion criteria, the pathological diagnosis was noninvasive breast cancer (2)Using other drugs that affect myelosuppression, such as immunosuppressants and anti-inflammatory drugs (3)Unwilling to participate in or cooperate with treatment

Design outcomes

Primary

MeasureTime frame
NEUT;WBC;PLT;HGB;

Secondary

MeasureTime frame
Degree of neutropenia;Time of G-CSF intervention;stratified analysis;Delayed chemotherapy or not;With or without chemotherapy reduction;Gastrointestinal reactions;Quality of life assessments (QOL);liver and kidney function tests;scale;

Countries

China

Contacts

Public ContactXieXiaohong

The First Affiliated Hospital of Zhejiang Chinese Medical University

guxidong@163.com+86 13957101427

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026